Article ; Online: APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Current atherosclerosis reports
2023 Volume 25, Issue 3, Page(s) 67–76
Abstract: Purpose of review: Apolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, ...
Abstract | Purpose of review: Apolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. This review summarizes the different functions of ApoC-III and underlines the recent findings related to its multifaceted pathophysiological role. Recent findings: The role of ApoC-III has been implicated in HDL metabolism and in the development of atherosclerosis, inflammation, and ER stress in endothelial cells. ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia (PPT). The emerging evidence of the involvement of ApoC-III in the in the pathogenesis of Alzheimer's disease open the way to further study if modification of ApoC-III level slows disease progression. Furthermore, ApoC-III is clearly linked to cardiovascular disease (CVD) risk, and progression of coronary artery disease (CAD) as well as the calcification of aortic valve and recent clinical trials has pointed out the inhibition of ApoC-III as a promising approach to manage hypertriglyceridemia and prevent CVD. Several evidences highlight the role of ApoC-III not only in triglyceride metabolism but also in several cardio-metabolic pathways. Results from recent clinical trials underline that the inhibition of ApoC-III is a promising therapeutical strategy for the management of severe hypertriglyceridemia and in CVD prevention. |
---|---|
MeSH term(s) | Humans ; Apolipoprotein C-III/metabolism ; Coronary Artery Disease/complications ; Endothelial Cells/metabolism ; Hypertriglyceridemia/metabolism ; Lipid Metabolism ; Triglycerides/metabolism |
Chemical Substances | Apolipoprotein C-III ; Triglycerides ; APOC3 protein, human |
Language | English |
Publishing date | 2023-01-23 |
Publishing country | United States |
Document type | Journal Article ; Review ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2057369-8 |
ISSN | 1534-6242 ; 1523-3804 |
ISSN (online) | 1534-6242 |
ISSN | 1523-3804 |
DOI | 10.1007/s11883-023-01080-8 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5534: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.